These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34435168)

  • 21. Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
    Bonadioa RC; Velho PI; Marta GN; Nardo M; Souza MC; Muniz DQ; Bezerra RO; Bispo RK; Faraj SF; Bastos DA; Dzik C
    Ecancermedicalscience; 2019; 13():973. PubMed ID: 31921344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real World Data of Diagnosis, Survival, and Treatment Outcomes in Patients With Metastatic Non Clear Cell Renal Cell Carcinoma.
    Izarn F; Allignet B; Gille R; Boyle H; Neidhardt EM; Négrier S; Fléchon A
    Clin Genitourin Cancer; 2023 Apr; 21(2):e35-e43. PubMed ID: 36272959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of immunotherapy in non-clear cell renal cell carcinoma.
    Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
    Front Oncol; 2023; 13():941835. PubMed ID: 36816976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advanced Non-Clear Cell Renal Cell Carcinoma Treatments and Survival: A Real-World Single-Centre Experience.
    Bimbatti D; Pierantoni F; Lai E; Ballestrin M; Cavasin N; Erbetta E; De Toni C; Basso U; Maruzzo M
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study.
    Buti S; Bersanelli M; Maines F; Facchini G; Gelsomino F; Zustovich F; Santoni M; Verri E; De Giorgi U; Masini C; Morelli F; Vitale MG; Sava T; Prati G; Librici C; Fraccon AP; Fornarini G; Maruzzo M; Leonardi F; Caffo O
    Clin Genitourin Cancer; 2017 Aug; 15(4):e609-e614. PubMed ID: 28108284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma.
    Naik P; Dudipala H; Chen YW; Rose B; Bagrodia A; McKay RR
    Ther Adv Urol; 2024; 16():17562872241232578. PubMed ID: 38434237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.
    Park I; Lee SH; Lee JL
    Clin Genitourin Cancer; 2018 Oct; 16(5):e997-e1002. PubMed ID: 29903415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
    Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical appraisal of systemic treatment options for metastatic non-clear cell renal cell carcinoma.
    Ismail S; Meskawi M; Hansen J; Bianchi M; Tian Z; Latour M; Graefen M; Montorsi F; Trinh QD; Perrotte P; Karakiewicz PI; Sun M
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):49-57. PubMed ID: 24411587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study.
    Vogelzang NJ; Olsen MR; McFarlane JJ; Arrowsmith E; Bauer TM; Jain RK; Somer B; Lam ET; Kochenderfer MD; Molina A; Doshi G; Lingerfelt B; Hauke RJ; Gunuganti V; Schnadig I; Van Veldhuizen P; Fleming M; Galamaga R; Gupta M; Hool H; Hutson T; Zhang J; McHenry MB; Johansen JL; Tykodi SS
    Clin Genitourin Cancer; 2020 Dec; 18(6):461-468.e3. PubMed ID: 32718906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities.
    Zarrabi K; Walzer E; Zibelman M
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial.
    Tykodi SS; Gordan LN; Alter RS; Arrowsmith E; Harrison MR; Percent I; Singal R; Van Veldhuizen P; George DJ; Hutson T; Zhang J; Zoco J; Johansen JL; Rezazadeh Kalebasty A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35210307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Randomized Phase IIa Trial with Temsirolimus versus Sunitinib in Advanced Non-Clear Cell Renal Cell Carcinoma: An Intergroup Study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German Cancer Society.
    Bergmann L; Grünwald V; Maute L; Grimm MO; Weikert S; Schleicher J; Klotz T; Greiner J; Flörcken A; Hartmann A; Gauler T
    Oncol Res Treat; 2020; 43(7-8):333-339. PubMed ID: 32541143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
    Zoumpourlis P; Genovese G; Tannir NM; Msaouel P
    Clin Genitourin Cancer; 2021 Apr; 19(2):103-116. PubMed ID: 33358151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview.
    Bergmann L; Weber S; Hartmann A; Ahrens M
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1273-1286. PubMed ID: 34291700
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
    Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
    Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study.
    Massari F; Mollica V; Fiala O; De Giorgi U; Kucharz J; Vitale MG; Molina-Cerrillo J; Facchini G; Seront E; Lenci E; Bourlon MT; Carrozza F; Pichler R; Lolli C; Myint ZW; Kanesvaran R; Torniai M; Rescigno P; Gomez de Liaño A; Zakopoulou R; Buti S; Porta C; Grande E; Santoni M
    Eur Urol Oncol; 2024 Oct; 7(5):1123-1131. PubMed ID: 38575409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma.
    Donskov F; Pinto CA; Predoiu R; Fox C; Georgsen JB; Skaarup K; Burcu M; Perini R; Steiniche T
    Acta Oncol; 2022 Oct; 61(10):1268-1277. PubMed ID: 36112410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
    Ito K
    Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.